This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ANI Pharmaceuticals, Inc.
Drug Names(s): female testosterone gel, transdermal testosterone
Description: LibiGel is a gel formulation of bio-identical testosterone that utilizes Antares Pharma's ATD technology and is designed to be quickly absorbed through the skin after application on the arms, shoulders, or abdomen, delivering testosterone to the bloodstream evenly over time in a non-invasive and painless manner. Although generally characterized as a male hormone, testosterone is also present in women, and its deficiency has been found to decrease libido or sex drive.
BioSante and Permatec
In June 2000, BioSante Pharmaceuticals signed an in-license agreement covering four hormone products for the treatment of testosterone deficiency in men and estrogen deficiency in women. The license agreement was signed with Permatec Technologie, AG of Switzerland. Under terms of the license agreement signed with Permatec, BioSante acquired exclusive marketing rights, with the right to grant sub-licenses, tothe three testosterone and estradiol products for all therapeutic indications in the U.S., Canada, Mexico, Israel, Australia, New Zealand, China, Malaysia, Indonesia and South Africa. BioSante will make an upfront payment, expects to fund the development of the products, make milestone payments and once regulatory approval to market is received, pay royalties on sales of the products.
In July 2013, ANI Pharmaceuticals announced the change of its name from BioSante Pharmaceuticals.
Antares (Medi-Ject) and Permatec
In July...See full deal structure in Biomedtracker
Partners: Antares Pharma, Inc.
Pink Sheet Intrinsa aftershocks?
Additional information available to subscribers only: